Member Info for gadgie

http://xcell.co.kr.

warming up nicely

https://affyxell-com.translate.goog/bbs/?so_table=news&PHPSESSID=1b4a4bd7f3328da8e465b2a847d9a4a4&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp&_x_tr_sch=http

Based on this, Daewoong Pharmaceutical will speed up its “All-in-one” business of cell, gene treatment, and advanced biomedicine, conducting production and development, quality test, licensing, storage, delivery, and sales.
http://www.koreabiomed.com/news/articleView.html?idxno=14199

?? : KBR(http://www.koreabiomed.com)

IMHO we are due updates anytime on both .... Daewoong undisclosed targets and Affyxell
AFX-001 pre clinical anytime
AFX-002 pre clinical due before year end
Stage : Discovery
Cell type : Engineered MSC
MoA : Suppression of T-cell mediated B-cell activation
Target : undisclosed
Dose Route : Intravenous Injection
Pre-clinical stage will begin in 2022

Stage : Discovery
Cell type : Engineered MSC
MoA : Inhibition of T-cell proliferation & cytokine production
Target : undisclosed
Dose Route : Intravenous Injection
Pre-clinical stage will begin in end of 2022

If the pre|CISION platform proves to work, then Avacta will be able to rapidly expand it to lots of other chemotherapy drugs. It has already begun development of pre|CISION pro-drug forms of Velcade, Oxaliplatin and Paclitaxel.

The chemotherapy market is expected to grow to $56 billion by 2024. If Avacta is successfully able to revolutionise the current drugs, they will obviously be able to capture a large share of this. At the same time, we would have a much better tool to fight cancer with. This is certainly a win-win.
https://alexanderrand.com/invest/avacta-the-next-roche/

Interesting price list ...lots of Affimers
https://www-cosmobio-co-jp.translate.goog/product/detail/affimer-product-als.asp?entry_id=14177&_x_tr_sl=ja&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc

Can Affimers be introduced to Electroporation ?
https://bioprocessintl.com/bioprocess-insider/deal-making/lg-chem-licensing-electroporation-tech-from-maxcyte/
According to MaxCyte, the partnership will support LG Chem’s CAR-T programs for solid tumors, including LR19023, which is in the pre-clinical stage and being developed as a solid cancer therapeutic. In return, MaxCyte, will receive platform licensing fees and program-related revenue.

Yes yet another Great find thank you ....gmcc

Interested on thoughts does anyone see us listing on Nasdaq ? N Bell first hand knowledge of doing this ... no doubt Ava 6000 takes us to the next inflection point

Thankyou GMCC … Excellent

Also :
https://abstracts.isth.org/abstract/the-use-of-plasminogen-activator-inhibitor-1-specific-affimers-as-a-tool-to-modulate-fibrin-clot-properties-and-thrombosis-risk/

This work provides proof of concept that PI-binding Affimers can alter protein function and may be a future tool to modulate fibrin clot lysis and reduce vascular thrombotic events in high risk populations.

https://abstracts.isth.org/abstract/modulation-of-plasmin-inhibitor-activities-using-affimer-technology-improves-the-hypofibrinolytic-environment-in-high-vascular-risk-individuals/

could this be the place we divulge more in Nov ?

https://www.pegsummiteurope.com

The following patents are patents granted by Daewoong Pharmaceutical and Avacta - Patent 1: “Method for producing mesoderm stem cells from human pluripotent stem cells and mesoderm stem cells produced thereby” patents registered in 8 countries - Patent 2: Registered patents for “Modified stefin A scaffold proteins” in 4 countries
https://www-koreabio-org.translate.goog/m48_view.php?idx=11&_x_tr_sl=ko&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc

CEO Yoo, who is leading Apicell Therapeutics, has accumulated R&D experience in biopharmaceutical and genome fields through Samsung Advanced Institute of Technology, Samsung Bioepis, and Theragen Bio. Afterwards, he served as the head of the cell therapy center and the head of the C&D center of Daewoong Pharmaceutical. .

When asked why he joined Apicell Therapeutics, CEO Yoo said, “When I served as the head of Daewoong Pharmaceutical’s cell therapy center, I fell in love with the potential and potential of the DW-MSC platform. For this reason, as the head of the C&D center, I was focused on finding a partner who could strengthen the immune function through genetic manipulation of mesenchymal stem cells. He also accepted this will at the level.”

CEO Yoo said, “Currently, AFX001, the first pipeline of Apicel Therapeutics, is about to transfer its technology to a GMP facility beyond the laboratory-level development stage. We plan to build a cell bank within this year and use it to produce drugs for clinical trials.”

CEO Yoo said, “We recently attracted investments in Series A and Bridge. We have secured research expenses for the next two to three years,” he said. At the same time, we will start the AFX001 clinical trial for organ transplant rejection and graft-versus-host disease to prove differentiated efficacy.”

Lastly, CEO Yoo expressed confidence that “Apicell Therapeutics wants to develop a stem cell-based CAR-T treatment.”

?? : ????(http://www.docdocdoc.co.kr)

https://www-docdocdoc-co-kr.translate.goog/news/articleView.html?idxno=2024632&_x_tr_sch=http&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=wapp
Interview] Jong-sang Yoo, CEO of Apicell
Therapeutics “Goal to develop CAR-T treatment for stem cell”

Recently, there is a company that draws attention from the industry by signing active partnerships with domestic bio companies. That's Apicell Therapeutics. GeneScript Probio, Biocytogen, and Korea Non-clinical Technology Support Center are showing off their presence by holding hands one after another.

In addition, it has a unique history of being a mesenchymal stem cell-based next-generation gene and cell therapy development company established through a joint investment between Daewoong Pharmaceutical, a domestic pharmaceutical company, and Avacta Life Science, a British company.

Accordingly, this paper met with Jongsang Yoo, CEO of Apicell Therapeutics in person to hear about Apicell Therapeutics' platform technology, future R&D plans, and mid- to long-term corporate vision.

First, when interest in gene and cell therapy is growing recently and many companies are jumping into R&D, when asked what Apicel Therapeutics' unique technology and strengths are, CEO Yoo Jong-sang said, "Securing excellent platform technology is difficult with other bio companies. It's different," he said.

CEO Yoo said, “The AFX platform technology developed by Apicell Therapeutics is based on Daewoong Pharmaceutical’s mesenchymal stem cell platform ‘DW-MSC’ technology. DW-MSC is a technology that overcomes the limitations of adult tissue-derived mesenchymal stem cells, which were difficult to subculture for a long time.”

He continued, “In addition, to further strengthen the immunomodulatory function, the analogue 'Affimer' developed by Avacta is applied through genetic manipulation. It is now possible to develop a stem cell treatment with enhanced immunomodulatory ability through genetic manipulation.”

If so, what was the reason for bringing the technologies of the two companies together?

Regarding this, CEO Yoo said, “Immune cell development and stem cell development started at the same time. In the case of immune cell development, innovation such as CAR-T treatment has been achieved, while stem cell development has been stagnant. “I came to the conclusion that innovation can only be achieved by applying genetic manipulation to stem cells, like CAR-T treatment, rather than just emphasizing culture technology,” he said.

He continued, "I was looking for another platform technology that could be fused through genetic manipulation, and the meeting with Avacta took place," he explained.

According to CEO Yoo, Daewoong Pharmaceutical, which has been discovering partners for stem cell treatment development, held its first meeting with Avacta at the 2018 Bio International (BIO USA) event. In January 2019, the following year, the two companies met again at the JP Morgan Bio Health Conference

Don't forget Affyxell
http://affyxell.com

3 x pre clinical any time soon

Once upon a Lifetime a company called Avacta came along ....Avacta made many people all over the world better ... Avacta changed Science as we know it today ....

Was it 4 million last year now 2 million love it